Institutional
ACORN CAPITAL ADVISORS, LLC
CIK 0002054410
$351.8M
Reported AUM
22
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · ACORN CAPITAL ADVISORS, LLC · Q1 2026
AI · grounded in 13F
ACORN CAPITAL ADVISORS, LLC established a new position in JBIO valued at $11.05M. The fund also initiated a new stake in KPTI for $1.6M and increased its holdings in CADL by 35.55%. Conversely, the fund closed its entire position in ACRV, resulting in a $976,622 reduction.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Ticker | Issuer | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|
| 1 | 430 | TERNS PHARMACEUTICALS INC | $92.1M | 26.17% | — | HELD |
| 2 | CGON | CG ONCOLOGY INC | $76.6M | 21.77% | -1,000 | -0.1% |
| 3 | URGN | UROGEN PHARMA LTD | $30.1M | 8.55% | +225,000 | +15.5% |
| 4 | PBYI | PUMA BIOTECHNOLOGY INC | $26.4M | 7.50% | — | HELD |
| 5 | TRVI | TREVI THERAPEUTICS INC | $25.6M | 7.27% | — | HELD |
| 6 | CADL | CANDEL THERAPEUTICS INC | $17.2M | 4.89% | +917,431 | +35.6% |
| 7 | BCAX | BICARA THERAPEUTICS | $12.8M | 3.64% | — | HELD |
| 8 | OKUR | ONKURE THERAPEUTICS INC | $11.8M | 3.34% | — | HELD |
| 9 | JBIO | JADE BIOSCEINCES INC | $11.1M | 3.14% | +786,760 | NEW |
| 10 | TARA | PROTARA THERAPEUTICS INC | $9.1M | 2.59% | — | HELD |
| 11 | VSTM | VERASTEM INC | $7.8M | 2.21% | — | HELD |
| 12 | HELP | HELUS PHARMA INC. | $7.4M | 2.10% | -32,757 | -2.1% |
| 13 | LONA | LEONABIO, INC. | $6.5M | 1.85% | +132,800 | +26.5% |
| 14 | AURA | AURA BIOSCIENCES INC | $4.0M | 1.13% | — | HELD |
| 15 | WHWK | WHITEHAWK THERAPEUTICS INC | $3.9M | 1.12% | — | HELD |
| 16 | CRDF | CARDIF ONCOLOGY INC | $2.9M | 0.81% | -200,000 | -10.2% |
| 17 | QTTB | Q32 BIO INC. | $2.0M | 0.57% | -178,373 | -36.1% |
| 18 | KPTI | KARYOPHARM THERAPEUTICS INC | $1.6M | 0.46% | +287,826 | NEW |
| 19 | JSPR | JASPER THERAPEUTICS | $1.2M | 0.35% | -375,000 | -21.0% |
| 20 | ASNSUSD | X4 PHARMACEUTICALS INC | $967K | 0.27% | -39,310 | -14.4% |
| 21 | BCABGBP | BIOATLA INC | $865K | 0.25% | +571,234 | +11.8% |
| 22 | VYNE | VYNE THERAPEUTICS INC | $855 | 0.00% | — | HELD |
| 23 | ACRV | ACRIVON THERAPEUTICS INC | — | — | -405,237 | EXITED |
Source: SEC EDGAR · accession 0001636587-26-000029. 13F discloses long positions only — shorts, foreign equities, and options are excluded.